OR2Z1 Antibody

What is OR2Z1 and why is it significant in research applications?

OR2Z1 (Olfactory Receptor Family 2 Subfamily Z Member 1) is a G-protein coupled receptor primarily known for its role in olfactory signaling. The scientific interest in OR2Z1 extends beyond olfaction, as olfactory receptors have been implicated in various non-canonical functions in multiple tissues.

The protein has a calculated molecular weight of approximately 34 kDa, although it often appears at around 72 kDa in experimental conditions due to post-translational modifications and/or dimerization . OR2Z1 is also sometimes referred to as OR2Z2 or Olfactory receptor OR19-4 in the literature .

Research significance:

• Expression in non-olfactory tissues suggests potential non-canonical functions

• Part of the G-protein coupled receptor 1 family, a major target for pharmaceutical research

• Potential roles in chemosensing in multiple tissue types

• Model system for studying receptor functionality and specificity

What are the validated applications for OR2Z1 antibodies in research?

OR2Z1 antibodies have been validated for multiple experimental applications with various degrees of optimization:

For optimal results, researchers should validate each application in their specific experimental system, as reactivity can vary between tissue types and experimental conditions .

How do you explain the discrepancy between predicted and observed molecular weight for OR2Z1?

The discrepancy between calculated molecular weight (~34 kDa) and observed molecular weight (~72 kDa) for OR2Z1 is a common technical consideration in OR2Z1 research:

Potential explanations:

• Post-translational modifications: G-protein coupled receptors frequently undergo glycosylation, phosphorylation, and other modifications that can substantially increase apparent molecular weight.

• Dimerization: OR2Z1 may form stable dimers resistant to denaturation, a common phenomenon among GPCRs.

• Detergent-resistant complexes: Membrane proteins like OR2Z1 can retain lipid associations or form complexes with other proteins even after standard sample preparation.

• Incomplete denaturation: The hydrophobic nature of transmembrane domains may cause incomplete unfolding, reducing electrophoretic mobility.

Methodological approach to resolve:

• Use multiple antibodies targeting different epitopes to confirm band identity

• Implement knockdown/knockout validation to confirm specificity

• Employ deglycosylation enzymes or other treatments to modify post-translational modifications

• Optimize sample preparation conditions (detergents, reducing agents, temperature)

What are the optimal protocols for using OR2Z1 antibodies in immunofluorescence studies?

Based on validated protocols from multiple sources, the following methodology is recommended for optimal OR2Z1 immunofluorescence:

Sample preparation:

• Fix cells with 4% paraformaldehyde (10-15 minutes at room temperature)

• Permeabilize with 0.1-0.2% Triton X-100 in PBS (5-10 minutes)

• Block with 1-5% BSA or normal serum (1 hour at room temperature)

Antibody incubation:

• Primary antibody: Use OR2Z1 antibody at 1:200-1:1000 dilution (optimal range determined from multiple suppliers)

• Incubate overnight at 4°C in humid chamber

• Wash 3× with PBS-T (PBS + 0.05% Tween-20)

• Secondary antibody: Use species-appropriate fluorophore-conjugated antibody at 1:500-1:2000

• Incubate 1-2 hours at room temperature

• Wash 3× with PBS-T

• Counterstain nuclei with DAPI

• Mount with anti-fade medium

Critical considerations:

• MCF7 cells show robust expression and are recommended as positive controls

• Include a peptide-blocking control by pre-incubating the antibody with immunizing peptide (201-250 or 68-96 amino acid regions, depending on the antibody used)

• Longer primary antibody incubation (up to 48 hours at 4°C) may improve signal-to-noise ratio for weak expression systems

How can researchers validate the specificity of OR2Z1 antibodies?

Comprehensive validation of OR2Z1 antibodies requires multiple orthogonal approaches:

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide

  • Use in parallel with untreated antibody

  • Specific signal should be eliminated in peptide-blocked samples

• Genetic knockdown/knockout:

  • Use siRNA targeting OR2Z1 (available from commercial suppliers)

  • CRISPR/Cas9-mediated knockout in cell lines

  • Compare antibody signal between control and KD/KO samples

• Orthogonal antibodies:

  • Test multiple antibodies targeting different epitopes

  • Concordant results with antibodies targeting different regions increase confidence

  • Available epitope regions include N-terminal (AA 68-96) and internal (AA 201-250)

• Cross-reactivity assessment:

  • Test in tissues/cells known to express OR2Z1

  • Test in tissues/cells lacking OR2Z1 expression

  • Include closely related olfactory receptors as specificity controls

• Western blot correlation:

  • Confirm that immunofluorescence pattern correlates with Western blot results

  • Confirm expected molecular weight bands (~72 kDa observed)

A combined approach using these validation methods substantially increases confidence in antibody specificity and experimental results .

What approaches can improve OR2Z1 antibody specificity for challenging research applications?

For challenging applications requiring enhanced specificity, researchers can employ several advanced techniques:

• Affinity purification of polyclonal antibodies:

  • Further purify commercially available antibodies using recombinant OR2Z1 protein

  • Immobilize purified OR2Z1 protein on a column

  • Selectively enrich for high-affinity antibodies

  • Remove cross-reactive antibodies

• Computational epitope design:

  • Utilize biophysics-informed computational modeling to design epitopes with minimal homology to related receptors

  • Select epitopes with maximum structural accessibility

  • Avoid regions with high sequence conservation among olfactory receptor family members

• Phage display selection:

  • Generate custom antibodies using phage display technology

  • Perform negative selection against closely related olfactory receptors

  • Conduct multiple rounds of selection with stringent washing

  • Isolate clones with highest specificity and affinity

• Machine learning-guided antibody optimization:

  • Apply machine learning algorithms to predict cross-reactivity based on epitope sequences

  • Utilize active learning strategies to improve antibody selection

  • Guide experimental design through computational prediction of binding profiles

• Single-chain variable fragments (scFvs):

  • Design atomically accurate scFvs targeting unique epitopes of OR2Z1

  • Combine with yeast display screening for optimal performance

  • Enable precise epitope targeting with reduced background

These approaches have been successfully applied to generate highly specific antibodies against challenging targets and can be adapted for OR2Z1 research .

How should researchers approach experimental design when characterizing new OR2Z1 antibodies?

A systematic characterization approach for OR2Z1 antibodies should include:

Phase 1: Basic characterization

• ELISA against recombinant OR2Z1 protein/peptide

  • Determine EC50 values

  • Assess binding kinetics

  • Compare against reference antibodies

• Western blot analysis

  • Test multiple cell lines (MCF7 recommended as a positive control)

  • Determine optimal concentration range (typically 1:500-1:2000)

  • Document observed molecular weight (expected ~72 kDa)

Phase 2: Cellular localization

• Immunofluorescence/Immunocytochemistry

  • Compare staining patterns across multiple fixation methods

  • Document subcellular localization

  • Include negative controls (peptide blocking)

• Flow cytometry

  • Optimize for cell surface versus permeabilized staining

  • Determine sensitivity thresholds

  • Establish fluorescence intensity correlation with expression levels

Phase 3: Advanced characterization

• Epitope mapping

  • Identify precise binding region

  • Compare with known functional domains

  • Assess potential interference with protein function

• Cross-reactivity assessment

  • Test against closely related olfactory receptors

  • Evaluate species cross-reactivity (human, mouse, rat)

  • Document any off-target binding

• Application-specific validation

  • Optimize protocols for specialized techniques

  • Validate in relevant biological systems

  • Document limitations and optimal conditions

This systematic approach ensures comprehensive characterization and documentation of antibody performance across multiple applications .

What methods can resolve contradictory results between different OR2Z1 antibodies?

When facing contradictory results between different OR2Z1 antibodies, implement this systematic resolution strategy:

• Epitope comparison analysis:

  • Map the binding epitopes of each antibody

  • Different antibodies may detect different isoforms or post-translationally modified variants

  • Create an epitope map against the full OR2Z1 sequence to identify potential differences

• Validation with genetic approaches:

  • Implement siRNA knockdown of OR2Z1

  • Create CRISPR/Cas9 knockout cell lines

  • Compare antibody performance in these controlled systems

  • True OR2Z1 antibodies should show signal reduction in knockdown/knockout systems

• Orthogonal detection methods:

  • Correlate antibody results with mRNA expression (qPCR, RNA-seq)

  • Use mass spectrometry to confirm protein identity

  • Employ tagged OR2Z1 expression systems as definitive controls

  • Reconcile discrepancies through multiple detection modalities

• Advanced binding kinetics analysis:

  • Use Biolayer Interferometry (BLI) or Surface Plasmon Resonance (SPR)

  • Determine precise binding affinities (KD values)

  • Compare on/off rates between antibodies

  • Identify potential avidity effects in polyclonal preparations

• Reconciliation framework:

This systematic approach can differentiate between genuine biological variations and technical artifacts when using different OR2Z1 antibodies .

What are the considerations for using OR2Z1 antibodies across different species?

When utilizing OR2Z1 antibodies across species, researchers should consider:

Sequence homology assessment:

• Human OR2Z1 shares variable homology with orthologs in other species

• Epitope sequence alignment is critical for predicting cross-reactivity

• Many commercial antibodies report reactivity with human, mouse, and rat OR2Z1

Species validation hierarchy:

• Direct validation: Experimentally confirm reactivity in each species

• Epitope conservation: Compare epitope sequence across species

• Vendor claims: Consider but independently verify cross-reactivity claims

• Literature precedent: Review published cross-species applications

Cross-reactivity optimization strategies:

• Select antibodies raised against conserved epitopes when cross-species reactivity is desired

• Consider species-specific antibodies for maximum specificity

• Validate with positive and negative controls from each species

• Adjust protocols for species-specific optimization (different blocking agents, incubation times)

Species-specific considerations:

• Human: Higher background in certain tissues, optimize blocking conditions

• Mouse: Potential cross-reactivity with closely related olfactory receptors

• Rat: May require higher antibody concentrations for equivalent signal

• Other species: Limited validation data available, extensive controls recommended

A phylogenetic approach to antibody selection and validation is recommended when working across species to maximize reliability of comparative studies.

How are computational approaches enhancing OR2Z1 antibody design and selection?

Recent advances in computational biology have revolutionized antibody design, with applications for OR2Z1 research:

• Structure-guided epitope selection:

  • Computational prediction of OR2Z1 protein structure

  • Identification of surface-exposed, unique epitopes

  • Selection of regions with minimal homology to related proteins

  • Optimization for accessibility and immunogenicity

• Machine learning for specificity prediction:

  • Training models on antibody-antigen binding data

  • Prediction of cross-reactivity with related olfactory receptors

  • Identification of optimal CDR (Complementarity-Determining Region) sequences

  • Active learning approaches to iteratively improve predictions

• De novo antibody design:

  • RFdiffusion for atomic-level antibody design

  • Generation of single-chain variable fragments (scFvs) with predefined binding properties

  • Computational design of both heavy and light chain CDRs

  • In silico affinity maturation simulations

• Library design and screening optimization:

  • Computational design of focused antibody libraries

  • Predictive modeling for phage display outcomes

  • Optimization of selection strategies based on structural information

  • Simulation of binding energetics for candidate antibodies

• Recent technological breakthrough example:
  "Recent work combining computational protein design using fine-tuned RFdiffusion network with yeast display screening has enabled the generation of antibodies that bind user-specified epitopes with atomic-level precision. This approach establishes a framework for rational computational design, screening, isolation, and characterization of fully de novo antibodies with precision in both structure and epitope targeting."

These computational approaches significantly reduce experimental iterations needed for developing highly specific OR2Z1 antibodies and enable targeting of previously challenging epitopes .

What are the emerging applications of OR2Z1 antibodies in advanced research contexts?

OR2Z1 antibodies are finding utility in several cutting-edge research applications:

• Single-cell proteomics:

  • Implementation in mass cytometry (CyTOF) panels

  • Integration with single-cell RNA sequencing data

  • Correlation of protein expression with transcriptional profiles

  • Resolution of cell-type specific expression patterns

• Spatial biology applications:

  • Multiplex immunofluorescence imaging to map OR2Z1 distribution

  • Correlation with tissue microenvironment features

  • Co-expression analysis with interacting proteins

  • Spatial transcriptomics integration for multi-omics approaches

• Proximity labeling studies:

  • Identification of OR2Z1 protein interaction networks

  • BioID or APEX2 fusion proteins for proximity proteomics

  • Validation of interactions using co-immunoprecipitation with OR2Z1 antibodies

  • Mapping of signaling complexes in different cellular contexts

• Therapeutic antibody development:

  • Potential targeting of OR2Z1 in contexts where it may be dysregulated

  • Development of antibody-drug conjugates for targeted therapy

  • Creation of bispecific antibodies to modulate OR2Z1 signaling

  • Humanized antibodies for potential clinical applications

• Synthetic biology applications:

  • Engineering of synthetic signaling systems based on OR2Z1

  • Creation of reporter systems using OR2Z1 antibodies

  • Development of chimeric antigen receptors (CARs) targeting OR2Z1

  • Antibody-guided protein degradation systems

These emerging applications highlight the expanding utility of OR2Z1 antibodies beyond traditional research applications, driving innovation in multiple fields .

How can researchers evaluate antibody affinity and avidity for OR2Z1?

Comprehensive evaluation of OR2Z1 antibody binding properties requires multiple complementary approaches:

Affinity measurement techniques:

• Surface Plasmon Resonance (SPR):

  • Gold standard for real-time, label-free affinity determination

  • Measures association (kon) and dissociation (koff) rate constants

  • Calculates equilibrium dissociation constant (KD)

  • Can distinguish between monovalent and bivalent binding

• Biolayer Interferometry (BLI):

  • Alternative optical technique for kinetic analysis

  • Particularly useful for OR2Z1 where dissociation constant (KD) values typically range from 2-11 nM for high-affinity antibodies

  • Allows competition assays to determine epitope overlap

  • Enables high-throughput screening of multiple antibodies

• Isothermal Titration Calorimetry (ITC):

  • Direct measurement of binding thermodynamics

  • Provides enthalpy (ΔH) and entropy (ΔS) values

  • Label-free approach

  • Particularly valuable for conformational epitopes

• Enzyme-Linked Immunosorbent Assay (ELISA):

  • Determination of EC50 values

  • Comparison of relative binding strengths

  • High-throughput format for antibody screening

  • Typical dilutions for OR2Z1 antibodies range from 1:10,000 to 1:20,000

Avidity analysis methods:

The recommended approach combines multiple methods to establish a comprehensive binding profile, enabling selection of optimal antibodies for specific research applications .

What are the recommended fixation and antigen retrieval methods for OR2Z1 immunohistochemistry?

Optimal detection of OR2Z1 in tissue sections requires careful consideration of fixation and antigen retrieval conditions:

Fixation protocols:

• Formalin fixation (FFPE tissues):

  • 10% neutral buffered formalin for 24-48 hours

  • Paraffin embedding using standard protocols

  • 4-5 μm section thickness recommended

  • Requires robust antigen retrieval (see below)

• Fresh-frozen tissue preparation:

  • Snap freezing in liquid nitrogen or isopentane

  • OCT compound embedding

  • 8-10 μm cryosection thickness optimal

  • Fixation in cold acetone (10 minutes) or 4% paraformaldehyde (10 minutes)

  • Generally provides better epitope preservation for OR2Z1

Antigen retrieval methods (ranked by effectiveness for OR2Z1):

• Heat-induced epitope retrieval (HIER):

  • Citrate buffer (pH 6.0), 95-98°C for 20 minutes

  • EDTA buffer (pH 8.0-9.0), 95-98°C for 20 minutes

  • Pressure cooker method often yields superior results

  • Allow 20-30 minutes cooling period after heating

• Proteolytic enzyme digestion:

  • Proteinase K (10-20 μg/ml) for 10-15 minutes at 37°C

  • Less consistent results than HIER methods

  • May cause tissue degradation if overdigested

  • Better for certain epitopes depending on antibody

• Combination approach:

  • Mild protease treatment (5 minutes) followed by HIER

  • Can improve accessibility of certain epitopes

  • Requires careful optimization for each tissue type

  • Particularly useful for heavily fixed samples

Optimization considerations:

• Fresh-frozen sections generally require less aggressive antigen retrieval

• Longer fixation times require more rigorous retrieval methods

• Overfixation may permanently mask certain epitopes

• Different OR2Z1 antibodies may have different optimal retrieval conditions based on epitope location

How can researchers optimize Western blot protocols for OR2Z1 detection?

Successful Western blot analysis of OR2Z1 requires careful optimization due to the nature of this membrane protein:

Sample preparation optimization:

• Lysis buffer selection:

  • RIPA buffer with 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS

  • Consider addition of 1% Triton X-100 for improved solubilization

  • Always include protease inhibitor cocktail

  • Optimization of detergent concentration crucial for membrane proteins

• Protein extraction conditions:

  • Mechanical disruption (homogenization or sonication) recommended

  • 30-minute lysis on ice with intermittent vortexing

  • Centrifugation at 14,000 × g for 15 minutes to clear lysate

  • Optional second extraction of pellet to improve recovery

Electrophoresis and transfer parameters:

• Gel percentage and preparation:

  • 10-12% polyacrylamide gels recommended

  • Load 25-50 μg total protein per lane

  • Include positive control (MCF7 cell lysate)

  • Denature samples at 70°C (not 95°C) for 10 minutes to prevent aggregation

• Transfer conditions:

  • Semi-dry transfer: 15V for 30 minutes

  • Wet transfer: 30V overnight at 4°C

  • PVDF membrane (0.45 μm) preferred over nitrocellulose

  • Addition of 0.1% SDS to transfer buffer can improve transfer efficiency

Antibody incubation optimization:

• Blocking conditions:

  • 5% non-fat dry milk in TBST (preferred)

  • 3-5% BSA in TBST (alternative)

  • 1 hour at room temperature or overnight at 4°C

  • Higher blocking agent concentration may reduce background

• Antibody dilutions:

  • Primary antibody: 1:500 - 1:2000 in blocking buffer

  • Overnight incubation at 4°C recommended

  • Secondary antibody: 1:5000 - 1:10000 for 1 hour at room temperature

  • Multiple washing steps (3 × 10 minutes) critical for specificity

Special considerations:

• The observed molecular weight of ~72 kDa differs from calculated (~34 kDa)

• Multiple bands may represent different glycosylation states

• Heat-induced aggregation can occur with membrane proteins

• Consider using gradient gels for better resolution of potential isoforms

What approaches can detect low-abundance OR2Z1 expression in challenging samples?

For samples with low OR2Z1 expression levels, several signal amplification strategies can be employed:

Signal amplification methodologies:

• Tyramide Signal Amplification (TSA):

  • Enzymatic deposition of fluorescent or chromogenic tyramide

  • 10-100 fold signal enhancement

  • Compatible with immunohistochemistry and immunofluorescence

  • Requires careful optimization to prevent background

• Polymer-based detection systems:

  • HRP-polymer conjugated secondary antibodies

  • Increased sensitivity compared to conventional ABC methods

  • Reduced background and faster protocols

  • Compatible with automated platforms

• Near-infrared (NIR) fluorescence amplification:

  • Plasmonic gold substrates for signal enhancement

  • Particularly effective for low-abundance antigens

  • Reduced autofluorescence interference

  • Superior signal-to-noise ratio

Sample enrichment approaches:

• Immunoprecipitation before Western blot:

  • Concentrate OR2Z1 from larger sample volumes

  • Use purified antibody coupled to protein A/G beads

  • Elute under mild conditions to preserve epitopes

  • Follow with standard Western blot protocol

• Cell/tissue fractionation:

  • Isolate membrane fractions to enrich for OR2Z1

  • Sucrose gradient ultracentrifugation for refined separation

  • Detergent phase partitioning for membrane protein isolation

  • Substantial enrichment compared to whole cell lysates

Specialized detection techniques:

• Proximity Ligation Assay (PLA):

  • Single-molecule detection capability

  • Visualization of protein-protein interactions

  • Rolling circle amplification provides dramatic sensitivity increase

  • Particularly useful for tissue samples with low expression

• Single-molecule array (Simoa) technology:

  • Digital counting of individual immunocomplexes

  • Femtomolar to attomolar detection limits

  • Bead-based isolation of individual complexes

  • Order of magnitude more sensitive than ELISA

These approaches can be combined for additive sensitivity gains when dealing with particularly challenging samples .